Century Therapeutics, Inc.
IPSC
$2.21
$0.094.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -13.15% | -12.57% | |||
| Gross Profit | 13.15% | 12.57% | |||
| SG&A Expenses | 42.93% | -14.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.27% | -12.91% | |||
| Operating Income | 0.27% | 12.91% | |||
| Income Before Tax | -12.51% | 44.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.90% | 44.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.90% | 44.31% | |||
| EBIT | 0.27% | 12.91% | |||
| EBITDA | -2.17% | 16.06% | |||
| EPS Basic | 49.04% | 44.84% | |||
| Normalized Basic EPS | 56.18% | 13.46% | |||
| EPS Diluted | 49.04% | 45.10% | |||
| Normalized Diluted EPS | 56.18% | 13.46% | |||
| Average Basic Shares Outstanding | 121.65% | 0.95% | |||
| Average Diluted Shares Outstanding | 121.65% | 0.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||